ANNUAL REPORT 2002
|
|
|
|
|
 |
|
COMPANY PROFILE
|
BIOPURE CORPORATION'S mission is to introduce revolutionary new drugs that
deliver lifesaving oxygen. The company has pioneered the development and manufacture of oxygen therapeutics, a new
class of intravenously administered pharmaceuticals that deliver oxygen to the body's tissues. Biopure's products
represent a new Oxygen Bridge™ treatment approach for managing patients' oxygen requirements in a broad range
of potential medical applications, including as a treatment for acute anemia in surgery and trauma patients, as an
adjunct to cancer therapy and as a means of preventing tissue damage and organ dysfunction in ischemic conditions
such as heart attack and stroke. Hemopure® [hemoglobin glutamer – 250 (bovine)], Biopure's first-in-class product
for human use, is approved in South Africa to treat acutely anemic surgery patients, and to eliminate, reduce or
delay the need for allogeneic red blood cells in these patients. In October 2002, the U.S. Food and Drug Administration
(FDA) accepted for review Biopure's application to market Hemopure in the United States for a similar indication in orthopedic
surgery patients. Oxyglobin® [hemoglobin glutamer – 200 (bovine)], the company's veterinary product for the treatment
of anemia in dogs, is the only oxygen therapeutic approved by the FDA and the European Commission.
|
|
|
|
INVESTMENT HIGHLIGHTS
|
 |
World's first approved hemoglobin-based oxygen therapeutics for use in human and veterinary medicine
|
|
U.S. marketing application for Hemopure accepted and undergoing FDA review
|
|
Only company with two completed Phase III clinical trials of an oxygen therapeutic
|
|
Largest validated manufacturing capacity for hemoglobin-derived oxygen therapeutics
|
|
100 percent ownership of rights to patented products and manufacturing technology
|
|
Multi-billion dollar global market opportunity
|
|
|
| APPROVED PRODUCTS |
2 |
|
|
|
| HEMOPURE CLINICAL TRIALS |
>20 |
|
|
|
| HEMOPURE PATIENTS |
>800 |
|
|
|
| HEMOPURE COMPASSIONATE USE CASES |
>40 |
|
|
|
| PRECLINICAL STUDIES |
>180 |
|
|
|
| OXYGLOBIN UNITS SOLD |
>115K |
|
|
|
| U.S. PATENTS |
>20 |
|
|
|
|
|